# Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

> **NCT05394740** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Center Hospital East** · enrollment: 30 (actual)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Adenocarcinoma

## Interventions

- **DRUG:** Regorafenib
- **DRUG:** Nivolumab
- **DRUG:** CapeOX
- **DRUG:** FOLFOX regimen

## Key facts

- **NCT ID:** NCT05394740
- **Lead sponsor:** National Cancer Center Hospital East
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-06
- **Primary completion:** 2024-04-14
- **Final completion:** 2025-08-25
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05394740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05394740, "Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05394740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*